BCI
ANIP icon

Brinker Capital Investments’s ANI Pharmaceuticals ANIP Stock Holding History

Brinker Capital Investments’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-67
Closed -$4K – 510
2017
Q3 		$4K Buy
+67
New +$3.19K ﹤0.01% 493

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Brinker Capital Investments's ANIP Position: Q4 2017 in Review

Brinker Capital Investments sold out of ANI Pharmaceuticals (ANIP) in Q4 2017, closing a stake of 67 shares — an estimated $4K sold.

Brinker Capital Investments first reported a position in ANIP in Q3 2017 and held it in 1 quarter. The position peaked at $4K in Q3 2017. 163 funds tracked by Wall St. Rank hold ANIP as of Q4 2017.

  • Brinker Capital Investments reported no remaining ANI Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Brinker Capital Investments sold 67 ANI Pharmaceuticals shares in Q4 2017, an estimated $4K.
  • Brinker Capital Investments first reported a position in ANI Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Brinker Capital Investments's ANI Pharmaceuticals position peaked at $4K in Q3 2017.
  • 163 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2017.

Based on Brinker Capital Investments's 13F filing for Q4 2017, filed 12 Feb 2018.